ArticleCancer diagnosis & prognosis
Ossification of Mandibular Central Giant Cell Granuloma (CGCG) in Neurofibromatosis Type 1 Patients.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: In patients afflicted with the autosomal dominant hereditary tumor predisposition syndrome neurofibromatosis type 1 (NF1), central giant cell granuloma of the jaw (CGCG) is observed in rare cases. In NF1, the lesion is caused by mutations in the Case Report: Both females with CGCG (age: 14 and 22 years) had either one or more jaw lesions. The lesions were removed with curettage to avoid dental injuries. In both cases, recurrences occurred, which led to re-ossification of the mandible through repeated surgical procedures after several years. The literature review based on 33 sufficiently documented cases shows clear differences between genders concerning the number of affected individuals in NF1. In addition, age at diagnosis of CGCG differed between NF1 patients compared to other RASopathies, namely Noonan syndrome. Cherubism-like lesions with tissue examination have only rarely been described in NF1 patients. In many reported cases surgical treatments were successful. However, in individual cases significantly mutilating interventions have been carried out, which raises questions about alternative treatment options. The proportion of purely diagnostic procedures without information about the further course is significant and limits information about the prognosis. Conclusion: NF1-associated CGCG have predominantly been treated surgically. In these patients, CGCG can also be expected beyond adolescence. The examination of NF1 patients should include the assessment of potential facial manifestations with appropriately selected imaging. Long-term monitoring of the findings is mandatory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.